Get the latest news, insights, and market updates on VTYX (Ventyx Biosciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, today announced entry into a definitive agreement for Lilly to acquire Ventyx. Jan 7, 2026 - $VTYX
Eli Lilly (LLY) Stock Is Up, What You Need To Know
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.3% in the morning session after the company announced a partnership to develop a new oral obesity drug and was reported to be in advanced talks to acquire Ventyx Biosciences for over $1 billion. Jan 7, 2026 - $VTYX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.